// App-Quantinova.ai

3266 : Antitumor activity of a combination of lenvatinib mesilate, ifosfamide, and etoposide against human pediatric osteosarcoma cell lines

Researchers

Presenter

  • Masahiro Matsuki

Principal Investigators

  • Kiyoshi Okamoto

  • Zoltan Dezso

  • Sergei I. Agoulnik

  • Yasuhiro Funahashi

  • Junji Matsui

Medical Centers

  • Eisai Co., Ltd., Tsukuba-city, Japan.

  • Eisai, Inc., Andover, MA

Locations

  • United States

  • Japan

Companies

  • Eisai Co., Ltd.

  • Eisai Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Thyroid Cancer

  • Osteosarcoma

  • Solid malignancies

Biomarkers

  • Platelet-derived growth factor receptor

  • Ret Proto-Oncogene

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

Drug/Treatment

  • Ifosfamide

  • Lenvatinib

  • Etoposide

  • Etoposide phosphate

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved